1
|
Bay-Jensen AC, Siebuhr AS, Damgaard D, Drobinski P, Thudium C, Mortensen J, Nielsen CH. Objective and noninvasive biochemical markers in rheumatoid arthritis: where are we and where are we going? Expert Rev Proteomics 2021; 18:159-175. [PMID: 33783300 DOI: 10.1080/14789450.2021.1908892] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
INTRODUCTION Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects approximately 1% of the adult population. RA is multi-factorial, and as such our understanding of the molecular pathways involved in the disease is currently limited. An increasing number of studies have suggested that several molecular phenotypes (i.e. endotypes) of RA exist, and that different endotypes respond differently to various treatments. Biochemical markers may be an attractive means for achieving precision medicine, as they are objective and easily obtainable. AREAS COVERED We searched recent publications on biochemical markers in RA as either diagnostic or prognostic markers, or as markers of disease activity. Here, we provide a narrative overview of different classes of markers, such as autoantibodies, citrulline products, markers of tissue turnover and cytokines, that have been tested in clinical cohorts or trials including RA patients. EXPERT OPINION Although many biochemical markers have been identified and tested, few are currently being used in clinical practice. As more treatment options are becoming available, the need for precision medicine tools that can aid physicians and patients in choosing the right treatment is growing.
Collapse
Affiliation(s)
- Anne C Bay-Jensen
- ImmunoScience, Nordic Bioscience Biomarkers and Research, Herlev, Denmark
| | - Anne Sofie Siebuhr
- ImmunoScience, Nordic Bioscience Biomarkers and Research, Herlev, Denmark
| | - Dres Damgaard
- Center for Rheumatolology and Spine Diseases, Institute for Inflammation Research, University of Copenhagen, Copenhagen Ø, Denmark
| | - Patryk Drobinski
- ImmunoScience, Nordic Bioscience Biomarkers and Research, Herlev, Denmark
| | - Christian Thudium
- ImmunoScience, Nordic Bioscience Biomarkers and Research, Herlev, Denmark
| | - Joachim Mortensen
- ImmunoScience, Nordic Bioscience Biomarkers and Research, Herlev, Denmark
| | - Claus H Nielsen
- Center for Rheumatolology and Spine Diseases, Institute for Inflammation Research, University of Copenhagen, Copenhagen Ø, Denmark
| |
Collapse
|
2
|
Rydell E, Forslind K, Nilsson JÅ, Karlsson M, Åkesson KE, Jacobsson LTH, Turesson C. Predictors of radiographic erosion and joint space narrowing progression in patients with early rheumatoid arthritis: a cohort study. Arthritis Res Ther 2021; 23:27. [PMID: 33446222 PMCID: PMC7809738 DOI: 10.1186/s13075-020-02413-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Accepted: 12/29/2020] [Indexed: 11/15/2022] Open
Abstract
Background Radiographic damage in rheumatoid arthritis (RA) includes erosions and joint space narrowing (JSN). Different mechanisms may underlie their development. The objective of this study was to evaluate predictors of these entities separately. Methods Consecutive early RA patients (symptom duration ≤12 months) from a defined area (Malmö, Sweden) recruited during 1995–2005 were investigated. Radiographs of hands and feet were scored by a trained reader according to the modified Sharp-van der Heijde score. Fat mass and lean mass distribution were measured at baseline using dual energy x-ray absorptiometry. Potential predictors of erosion and JSN progression from inclusion to the 5-year follow-up were evaluated. Results Two hundred and thirty-three patients were included. Radiographs at baseline and 5 years were available for 162 patients. The median (interquartile) progression of erosion and JSN scores were 4 (0–8) and 8 (1–16), respectively. Rheumatoid factor (RF) was a robust significant predictor of both erosion and JSN score progression. In adjusted analyses, anti-CCP antibodies predicted erosions while the erythrocyte sedimentation rate was predictive of both outcomes. Smoking and high baseline disease activity (DAS28 > 5.1) predicted progression of erosions. Baseline erosion score was associated with progression of both erosion and JSN progression, while baseline JSN score was predictive only of the progression of JSN. Overweight/obesity (BMI ≥ 25 kg/m2) was a significant negative predictor of JSN score progression (β = − 0.14, p = 0.018, adjusted for RF, age, baseline JSN score) also when additionally adjusting for ever smoking (p = 0.041). Among female patients, this effect was observed in those of estimated post-menopausal age (> 51 years), but not in younger women. The truncal to peripheral fat ratio was associated with less JSN score progression in women, but not in men. Conclusions Overweight RA patients had less JSN progression, independent of smoking status. This effect was seen in particular among older women (mainly post-menopausal), but not younger. Truncal fat was associated with less JSN progression in female patients. Smoking predicted erosion progression, and erosions may precede JSN. BMI and fat distribution may influence cartilage damage in early RA and might be related to hormonal factors.
Collapse
Affiliation(s)
- Emil Rydell
- Rheumatology, Department of Clinical Sciences Malmö, Lund University, Jan Waldenströms gata 1B, SE-205 02, Malmö, Sweden. .,Department of Rheumatology, Skåne University Hospital, Malmö, Sweden.
| | - Kristina Forslind
- Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.,Spenshult Research and Development Centre, Halmstad, Sweden
| | - Jan-Åke Nilsson
- Rheumatology, Department of Clinical Sciences Malmö, Lund University, Jan Waldenströms gata 1B, SE-205 02, Malmö, Sweden.,Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
| | - Magnus Karlsson
- Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.,Department of Orthopaedics, Skåne University Hospital, Malmö, Sweden
| | - Kristina E Åkesson
- Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.,Department of Orthopaedics, Skåne University Hospital, Malmö, Sweden
| | - Lennart T H Jacobsson
- Rheumatology, Department of Clinical Sciences Malmö, Lund University, Jan Waldenströms gata 1B, SE-205 02, Malmö, Sweden.,Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Göteborg, Sweden
| | - Carl Turesson
- Rheumatology, Department of Clinical Sciences Malmö, Lund University, Jan Waldenströms gata 1B, SE-205 02, Malmö, Sweden.,Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
| |
Collapse
|
3
|
Bone phenotypes in rheumatology - there is more to bone than just bone. BMC Musculoskelet Disord 2020; 21:789. [PMID: 33248451 PMCID: PMC7700716 DOI: 10.1186/s12891-020-03804-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Accepted: 11/17/2020] [Indexed: 12/14/2022] Open
Abstract
Osteoarthritis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, all have one clear common denominator; an altered turnover of bone. However, this may be more complex than a simple change in bone matrix and mineral turnover. While these diseases share a common tissue axis, their manifestations in the area of pathology are highly diverse, ranging from sclerosis to erosion of bone in different regions. The management of these diseases will benefit from a deeper understanding of the local versus systemic effects, the relation to the equilibrium of the bone balance (i.e., bone formation versus bone resorption), and the physiological and pathophysiological phenotypes of the cells involved (e.g., osteoblasts, osteoclasts, osteocytes and chondrocytes). For example, the process of endochondral bone formation in chondrocytes occurs exists during skeletal development and healthy conditions, but also in pathological conditions. This review focuses on the complex molecular and cellular taxonomy of bone in the context of rheumatological diseases that alter bone matrix composition and maintenance, giving rise to different bone turnover phenotypes, and how biomarkers (biochemical markers) can be applied to potentially describe specific bone phenotypic tissue profiles.
Collapse
|
4
|
Yukioka C, Ebina K, Shimaoka Y, Yukioka M, Yoshikawa H, Nakata K, Ochi T. Establishment of anti-C1q monoclonal antibodies to measure serum C1q levels discriminating disease severity subsets of rheumatoid arthritis within 5 years of onset. Mod Rheumatol 2019; 30:816-820. [PMID: 31422723 DOI: 10.1080/14397595.2019.1657653] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Objectives: To establish anti-C1q monoclonal antibodies which can measure serum C1q levels discriminating disease severity subsets of rheumatoid arthritis (RA) within 5 years of onset.Methods: In this multi-centre, longitudinal, observational study, 122 RA patients [102 females, baseline age 58.5 years, rheumatoid factor (RF) positivity 78.7%, serum C-reactive protein (CRP) 1.2 mg/dl, and concomitant methotrexate (MTX) 4.9 mg/week (29.5%)] within 5 years of onset (disease duration 21.0 months) were enrolled from 1985 to 2000. Patients were not treated by more than 8 mg/week of MTX or biologics which may strongly affect the course of joint destruction. Disease severity at 10-15 years of onset was classified according to the number of destructed joints of overall 68 joints on plain radiographs (36 patients were mild RA group involving only peripheral joints and 86 were severe RA group involving large axial joints). Baseline serum C1q levels were evaluated by ELISA with newly developed 4 monoclonal anti-C1q antibodies, and compared between two groups as well as conventional RA disease activity markers.Results: There were no significant differences between two groups in baseline conventional RA disease activity markers such as RF, erythrocyte sedimentation rate, CRP, and matrix metalloproteinase-3. However, compared to mild RA group, severe RA group showed higher baseline serum C1q levels (μg/ml) evaluated by anti-C1q monoclonal antibodies of no.33 (104.8 ± 22.3 vs. 118.3 ± 19.3; p = .0024), no. 40 (102.6 ± 21.9 vs 121.2 ± 22.3; p = .000069), no. 54 (102.1 ± 22.5 vs. 119.3 ± 26.9; p = .00052), and no. 76 (105.6 ± 21.8 vs. 122.6 ± 26.4; p = .00043). Receiver operating characteristic curve analysis revealed that in patients with serum C1q levels of ≥110.5 μg/ml (measured by antibody no. 40), 78.9% (75/95) belonged to severe RA group.Conclusion: Measuring serum C1q levels of RA within 5 years of onset by newly developed anti-C1q antibodies may be useful in predicting the prognosis of disease severity evaluated by the extent of joint destruction.
Collapse
Affiliation(s)
| | - Kosuke Ebina
- Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Yasunori Shimaoka
- Department of Orthopaedic Surgery, Hamawaki Orthopaedic Hospital, Hiroshima, Japan
| | - Masao Yukioka
- Department of Rheumatology, Yukioka Hospital, Osaka, Japan
| | - Hideki Yoshikawa
- Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Ken Nakata
- Department of Health and Sport Sciences, Osaka University Graduate School of Medicine, Osaka, Japan
| | | |
Collapse
|
5
|
Role of cartilage oligomeric matrix protein (COMP) as a prognostic biomarker in follow-up of early rheumatoid arthritis patients: Correlation to musculoskeletal ultrasonographic findings. EGYPTIAN RHEUMATOLOGIST 2018. [DOI: 10.1016/j.ejr.2018.01.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
6
|
Ebina K, Hirao M, Hashimoto J, Matsuoka H, Iwahashi T, Chijimatsu R, Etani Y, Okamura G, Miyama A, Yoshikawa H. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis. Osteoporos Int 2018; 29:1627-1636. [PMID: 29574517 DOI: 10.1007/s00198-018-4492-y] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Accepted: 03/16/2018] [Indexed: 11/25/2022]
Abstract
UNLABELLED In biologic-naïve female RA patients, switching oral BPs to DMAb significantly reduced radiographic joint destruction compared to continuing oral BPs or switching to TPTD at 12 months, which were significantly associated with a decrease of a bone resorption marker at 6 months. INTRODUCTION The aim of this study was to clarify the effects of switching oral bisphosphonates (BPs) to denosumab (DMAb) or daily teriparatide (TPTD) on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis (RA). METHODS A retrospective, case-controlled study involving 90 female RA patients (mean age 68.2 years, 96.7% postmenopausal, disease activity score assessing 28 joints with CRP (DAS28-CRP) 2.4, methotrexate treatment 81.1%, prednisolone treatment 68.9%, and prior BP treatment 44.8 months), who were allocated depending on each patient's and physician's wishes, to (1) the BP-continue group (n = 30), (2) the switch-to-DMAb group (n = 30), or (3) the switch-to-TPTD group (n = 30), was conducted. Patients were retrospectively selected to minimize the difference of possible clinical backgrounds that may affect the joint destruction of RA. The primary endpoint was to clarify the change of the modified total Sharp score (mTSS) from baseline to 12 months. RESULTS After 12 months, the mean changes of the modified Sharp erosion score were significantly lower in the switch-to-DMAb group (0.2 ± 0.1; mean ± standard error) than in the switch-to-TPTD group (1.3 ± 0.5; P < 0.05), and mTSS was significantly lower in the switch-to-DMAb group (0.3 ± 0.2) than in the BP-continue group (1.0 ± 0.3; P < 0.05) and the switch-to-TPTD group (1.7 ± 0.6; P < 0.05). The logistic regression analysis showed that mTSS changes were significantly associated with the percent changes of TRACP-5b at 6 months (β = 0.30, 95% CI = 0.002-0.016; P < 0.01). CONCLUSIONS Changes of systemic bone turnover induced by switching BPs to DMAb or TPTD may affect not only systemic bone mass, but also local joint destruction, and its clinical relevance should be considered comprehensively.
Collapse
Affiliation(s)
- K Ebina
- Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
| | - M Hirao
- Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - J Hashimoto
- Department of Rheumatology, National Hospital Organization, Osaka Minami Medical Center, 2-1 Kidohigashi, Kawachinagano, Osaka, 586-8521, Japan
| | - H Matsuoka
- Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - T Iwahashi
- Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - R Chijimatsu
- Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Y Etani
- Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - G Okamura
- Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - A Miyama
- Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - H Yoshikawa
- Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| |
Collapse
|
7
|
Sewerin P, Le L, Vordenbäumen S, Schleich C, Sengewein R, Brinks R, Pongratz G, Bleck E, Lesch J, Mansmann U, Schneider M, Ostendorf B. Rheumatoid Arthritis Magnetic Resonance Imaging Score Predicts Therapy Response: Results of the German ArthroMark Cohort. J Rheumatol 2018; 45:753-759. [PMID: 29606664 DOI: 10.3899/jrheum.170797] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/16/2018] [Indexed: 11/22/2022]
Abstract
OBJECTIVE Markers for treatment response in rheumatoid arthritis (RA) are lacking. The aim of the study was to assess the performance of the RA magnetic resonance imaging (MRI) scoring system (RAMRIS) in combination with serum biomarkers to predict response to methotrexate (MTX) treatment in therapy-naive patients with early RA by using high-field MRI. METHODS Twenty-eight patients with RA were prospectively assessed with baseline 3-T MRI of the clinical dominant hand, 3 and 6 months after MTX. The patients met the 2010 American College of Rheumatology/European League Against Rheumatism (EULAR) criteria [average age 56.8 yrs (range 39-74); positive for rheumatoid factor and/or anticyclic citrullinated peptide antibodies; disease duration < 6 mos (range 2-23 weeks)]. RAMRIS and serum biomarkers consisting of various experimental proteins including receptor activator of nuclear factor-κB ligand (RANKL) were obtained. Remission or treatment response was defined according to EULAR. To adjust for intrapersonal correlation, generalized linear mixed models were used. RESULTS Treatment response at 3 months was associated to low RAMRIS erosion subscores and low total RAMRIS scores (p = 0.019 and 0.03, respectively). Remission at 6 months was associated to low RANKL levels (p = 0.033). In multivariate analyses, response at 3 and 6 months was predicted more accurately with the inclusion of total RAMRIS score, RAMRIS synovitis subscore at the second metacarpophalangeal (MCP) joint, or a combination of the two (p value likelihood ratio test = 0.035, 0.035, and 0.041, respectively). Remission was more accurately predicted with inclusion of RANKL, with no significant predictive effect of MRI. CONCLUSION Baseline total RAMRIS can predict EULAR response. RAMRIS synovitis subscore at the second MCP joint and RANKL are associated with response and remission, respectively.
Collapse
Affiliation(s)
- Philipp Sewerin
- From the Department and Hiller-Research-Unit for Rheumatology, and the Institute of Diagnostic and Interventional Radiology, Universitätsklinikum Düsseldorf (UKD), Heinrich-Heine-University Düsseldorf; University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology, Düsseldorf; the Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University, Munich, Germany. .,P. Sewerin, MD, University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology; L. Le, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; S. Vordenbäumen, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; C. Schleich, MD, PhD, Department for Diagnostic and Interventional Radiology, UKD, Heinrich-Heine-University Düsseldorf; R. Sengewein, MD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; R. Brinks, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; G. Pongratz, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; E. Bleck, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; J. Lesch, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; U. Mansmann, PhD, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; M. Schneider, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; B. Ostendorf, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf.
| | - Lien Le
- From the Department and Hiller-Research-Unit for Rheumatology, and the Institute of Diagnostic and Interventional Radiology, Universitätsklinikum Düsseldorf (UKD), Heinrich-Heine-University Düsseldorf; University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology, Düsseldorf; the Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University, Munich, Germany.,P. Sewerin, MD, University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology; L. Le, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; S. Vordenbäumen, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; C. Schleich, MD, PhD, Department for Diagnostic and Interventional Radiology, UKD, Heinrich-Heine-University Düsseldorf; R. Sengewein, MD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; R. Brinks, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; G. Pongratz, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; E. Bleck, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; J. Lesch, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; U. Mansmann, PhD, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; M. Schneider, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; B. Ostendorf, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf
| | - Stefan Vordenbäumen
- From the Department and Hiller-Research-Unit for Rheumatology, and the Institute of Diagnostic and Interventional Radiology, Universitätsklinikum Düsseldorf (UKD), Heinrich-Heine-University Düsseldorf; University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology, Düsseldorf; the Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University, Munich, Germany.,P. Sewerin, MD, University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology; L. Le, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; S. Vordenbäumen, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; C. Schleich, MD, PhD, Department for Diagnostic and Interventional Radiology, UKD, Heinrich-Heine-University Düsseldorf; R. Sengewein, MD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; R. Brinks, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; G. Pongratz, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; E. Bleck, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; J. Lesch, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; U. Mansmann, PhD, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; M. Schneider, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; B. Ostendorf, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf
| | - Christoph Schleich
- From the Department and Hiller-Research-Unit for Rheumatology, and the Institute of Diagnostic and Interventional Radiology, Universitätsklinikum Düsseldorf (UKD), Heinrich-Heine-University Düsseldorf; University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology, Düsseldorf; the Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University, Munich, Germany.,P. Sewerin, MD, University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology; L. Le, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; S. Vordenbäumen, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; C. Schleich, MD, PhD, Department for Diagnostic and Interventional Radiology, UKD, Heinrich-Heine-University Düsseldorf; R. Sengewein, MD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; R. Brinks, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; G. Pongratz, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; E. Bleck, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; J. Lesch, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; U. Mansmann, PhD, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; M. Schneider, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; B. Ostendorf, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf
| | - Ruben Sengewein
- From the Department and Hiller-Research-Unit for Rheumatology, and the Institute of Diagnostic and Interventional Radiology, Universitätsklinikum Düsseldorf (UKD), Heinrich-Heine-University Düsseldorf; University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology, Düsseldorf; the Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University, Munich, Germany.,P. Sewerin, MD, University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology; L. Le, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; S. Vordenbäumen, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; C. Schleich, MD, PhD, Department for Diagnostic and Interventional Radiology, UKD, Heinrich-Heine-University Düsseldorf; R. Sengewein, MD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; R. Brinks, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; G. Pongratz, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; E. Bleck, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; J. Lesch, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; U. Mansmann, PhD, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; M. Schneider, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; B. Ostendorf, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf
| | - Ralph Brinks
- From the Department and Hiller-Research-Unit for Rheumatology, and the Institute of Diagnostic and Interventional Radiology, Universitätsklinikum Düsseldorf (UKD), Heinrich-Heine-University Düsseldorf; University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology, Düsseldorf; the Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University, Munich, Germany.,P. Sewerin, MD, University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology; L. Le, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; S. Vordenbäumen, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; C. Schleich, MD, PhD, Department for Diagnostic and Interventional Radiology, UKD, Heinrich-Heine-University Düsseldorf; R. Sengewein, MD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; R. Brinks, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; G. Pongratz, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; E. Bleck, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; J. Lesch, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; U. Mansmann, PhD, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; M. Schneider, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; B. Ostendorf, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf
| | - Georg Pongratz
- From the Department and Hiller-Research-Unit for Rheumatology, and the Institute of Diagnostic and Interventional Radiology, Universitätsklinikum Düsseldorf (UKD), Heinrich-Heine-University Düsseldorf; University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology, Düsseldorf; the Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University, Munich, Germany.,P. Sewerin, MD, University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology; L. Le, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; S. Vordenbäumen, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; C. Schleich, MD, PhD, Department for Diagnostic and Interventional Radiology, UKD, Heinrich-Heine-University Düsseldorf; R. Sengewein, MD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; R. Brinks, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; G. Pongratz, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; E. Bleck, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; J. Lesch, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; U. Mansmann, PhD, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; M. Schneider, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; B. Ostendorf, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf
| | - Ellen Bleck
- From the Department and Hiller-Research-Unit for Rheumatology, and the Institute of Diagnostic and Interventional Radiology, Universitätsklinikum Düsseldorf (UKD), Heinrich-Heine-University Düsseldorf; University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology, Düsseldorf; the Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University, Munich, Germany.,P. Sewerin, MD, University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology; L. Le, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; S. Vordenbäumen, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; C. Schleich, MD, PhD, Department for Diagnostic and Interventional Radiology, UKD, Heinrich-Heine-University Düsseldorf; R. Sengewein, MD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; R. Brinks, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; G. Pongratz, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; E. Bleck, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; J. Lesch, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; U. Mansmann, PhD, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; M. Schneider, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; B. Ostendorf, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf
| | - Juliane Lesch
- From the Department and Hiller-Research-Unit for Rheumatology, and the Institute of Diagnostic and Interventional Radiology, Universitätsklinikum Düsseldorf (UKD), Heinrich-Heine-University Düsseldorf; University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology, Düsseldorf; the Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University, Munich, Germany.,P. Sewerin, MD, University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology; L. Le, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; S. Vordenbäumen, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; C. Schleich, MD, PhD, Department for Diagnostic and Interventional Radiology, UKD, Heinrich-Heine-University Düsseldorf; R. Sengewein, MD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; R. Brinks, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; G. Pongratz, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; E. Bleck, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; J. Lesch, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; U. Mansmann, PhD, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; M. Schneider, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; B. Ostendorf, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf
| | - Ulrich Mansmann
- From the Department and Hiller-Research-Unit for Rheumatology, and the Institute of Diagnostic and Interventional Radiology, Universitätsklinikum Düsseldorf (UKD), Heinrich-Heine-University Düsseldorf; University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology, Düsseldorf; the Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University, Munich, Germany.,P. Sewerin, MD, University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology; L. Le, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; S. Vordenbäumen, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; C. Schleich, MD, PhD, Department for Diagnostic and Interventional Radiology, UKD, Heinrich-Heine-University Düsseldorf; R. Sengewein, MD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; R. Brinks, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; G. Pongratz, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; E. Bleck, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; J. Lesch, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; U. Mansmann, PhD, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; M. Schneider, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; B. Ostendorf, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf
| | - Matthias Schneider
- From the Department and Hiller-Research-Unit for Rheumatology, and the Institute of Diagnostic and Interventional Radiology, Universitätsklinikum Düsseldorf (UKD), Heinrich-Heine-University Düsseldorf; University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology, Düsseldorf; the Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University, Munich, Germany.,P. Sewerin, MD, University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology; L. Le, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; S. Vordenbäumen, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; C. Schleich, MD, PhD, Department for Diagnostic and Interventional Radiology, UKD, Heinrich-Heine-University Düsseldorf; R. Sengewein, MD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; R. Brinks, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; G. Pongratz, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; E. Bleck, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; J. Lesch, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; U. Mansmann, PhD, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; M. Schneider, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; B. Ostendorf, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf
| | - Benedikt Ostendorf
- From the Department and Hiller-Research-Unit for Rheumatology, and the Institute of Diagnostic and Interventional Radiology, Universitätsklinikum Düsseldorf (UKD), Heinrich-Heine-University Düsseldorf; University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology, Düsseldorf; the Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University, Munich, Germany.,P. Sewerin, MD, University Düsseldorf, Medical Faculty, Department of Endocrinology, Diabetology and Rheumatology; L. Le, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; S. Vordenbäumen, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; C. Schleich, MD, PhD, Department for Diagnostic and Interventional Radiology, UKD, Heinrich-Heine-University Düsseldorf; R. Sengewein, MD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; R. Brinks, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; G. Pongratz, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; E. Bleck, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; J. Lesch, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; U. Mansmann, PhD, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University; M. Schneider, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf; B. Ostendorf, MD, PhD, Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich-Heine-University Düsseldorf
| |
Collapse
|
8
|
Saghafi M, Khodashahi M, Saadati N, Azarian A, Rezaieyazdi Z, Salehi M, Sahebari M. Relationship between cartilage oligomeric matrix protein (COMP) and rheumatoid arthritis severity. Electron Physician 2017; 9:5940-5947. [PMID: 29560145 PMCID: PMC5843419 DOI: 10.19082/5940] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Accepted: 11/15/2017] [Indexed: 12/22/2022] Open
Abstract
Background Serum cartilage oligomeric matrix protein (COMP) is a non-collagen glycoprotein produced by the cartilage, synovium, tendon, and meniscus. Recent studies showed that COMP is a reliable factor for monitoring cartilage damage. Objective To determine the relationship between serum COMP concentration and the severity of rheumatoid arthritis (RA). Methods This cross-sectional study lasted from 2013 to 2015 at the Rheumatology Clinic of Ghaem Hospital, Mashhad, Iran. The study population consisted of eligible patients who presented to our clinic during the study period. Four groups (150 subjects) were included as early RA (50 patients), late RA (50 patients), grades II and III OA (osteoarthritis) (25 cases, 17 grade II and 8 grade III joint destruction), and healthy controls (25 individuals). These were included consecutively. Serum COMP level was assessed by sandwich ELISA technique. In addition, ESR, hs-CRP, serum RF, and anti-CCP were assayed. X-rays of the knees (in OA) and hands (in RA) were examined for the degree of joint damage/erosion using the Short Erosion Scale (SES) in RA and Kellgren-Lawrence grading in OA. Analysis of variance (ANOVA) to compare mean COMP level among the groups and ROC (Receiver Operating Characteristic) analysis to determine the diagnostic accuracy of COMP in diagnosis of late RA were used by SPSS software (ver. 20.0). Results Mean (±SD) serum COMP levels were 18 (±10.6) U/L in early RA, 19.3 (±9.6) U/L in late RA, 10.9 (±4.5) U/L in OA, and 4.2 (±3.8) in controls; p<0.001. Serum COMP level was higher in RA and OA groups when compared to control group. Mean (±SD) SES score was 13.5 (±7.5) in early RA and 16.4 (±9.7) in late RA (p=0.093). There was a significant positive correlation between COMP level and disease severity in early RA (r=0.677, p<0.001) as well as in late RA (r=0.753, p<0.001). Serum COMP level at a concentration of 15.25 U/L had a sensitivity of 68% and specificity of 70% to discriminate late RA from early RA (area under curve= 69% (95% CI: 58% to 79%; p=0.001). Conclusion COMP had positive significant correlation with early and late RA severity. This serum biomarker can be a useful and easy tool for monitoring of RA patients either at early or late stages of the disease.
Collapse
Affiliation(s)
- Massoud Saghafi
- MD of Rheumatology, Professor, Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Mandana Khodashahi
- MD of Rheumatology, Assistant Professor, Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Nayyereh Saadati
- MD of Rheumatology, Associate Professor, Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Azita Azarian
- MD of Radiology, Associate Professor, Department of Radiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Zahra Rezaieyazdi
- MD of Rheumatology, Professor, Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Maryam Salehi
- MD of Community Medicine, Associate Professor, Research Center for Patient Safety, Mashhad University of Medical Sciences, Mashhad, Iran.,Clinical Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Maryam Sahebari
- MD of Rheumatology, Associate Professor, Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| |
Collapse
|
9
|
Johansson L, Ärlestig L, Kokkonen H, Brink M, Rantapää-Dahlqvist S. An increased concentration of receptor activator of nuclear factor kappa-B ligand pre-dates the onset of rheumatoid arthritis. Rheumatology (Oxford) 2017; 56:2190-2196. [PMID: 29029341 DOI: 10.1093/rheumatology/kex339] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2017] [Indexed: 01/16/2023] Open
Abstract
Objectives RANK ligand (RANKL) is involved in destruction and osteoporosis in RA. In this study, the relationships between RANKL and ACPA, anti-carbamylated protein antibodies (anti-CarP), cytokines and chemokines were analysed in individuals before the onset of RA symptoms, and their associations with radiological findings at disease onset were assessed. Methods This was a case-control study performed within the Medical Biobank of Northern Sweden that included 470 pre-symptomatic individuals [334 women and 136 men; mean (s.d.) age 52.3 (9.4) years] using blood samples donated before symptom onset (pre-dating time; 5.0 years) and 96 controls (60 women and 36 men). Plasma was analysed for RANKL (BioVendor, Karasek, Brno, Czech Republic), anti-CCP2 antibodies (Eurodiagnostics, Malmö, Sweden), anti-CarP antibodies (in-house ELISA), ACPA specificities (ISAC-platform, Phadia AB, Uppsala, Sweden) and cytokines/chemokines (Meso Scale Discovery methods, Rockville, MD, USA). Radiographs of hands and feet were graded using the Larsen score. Results The concentration of RANKL was higher in the pre-symptomatic individuals compared with controls; mean (s.e.m.): 0.50 (0.03) vs 0.22 (0.02) nmol/l (P < 0.001). The concentration increased gradually over time until symptom onset but appeared later than ACPA/RF/anti-CarP antibodies. Positivity for these antibodies yielded higher levels of RANKL compared with seronegativity (P < 0.001). RANKL concentrations were significantly associated with IL-6 and IL-10 concentrations. The combination of positivity for RANKL and anti-CarP antibodies resulted in a higher Larsen score at diagnosis β = 6.18 (95% CI: 0.93, 11.43; P = 0.022). Conclusion RANKL concentrations were increased several years before symptom onset for RA, particularly in ACPA/RF/anti-CarP-positive individuals, all detectable earlier than RANKL. Positivity for RANKL and anti-CarP antibodies yielded the highest Larsen score at disease onset.
Collapse
Affiliation(s)
- Linda Johansson
- Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden
| | - Lisbeth Ärlestig
- Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden
| | - Heidi Kokkonen
- Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden
| | - Mikael Brink
- Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden
| | | |
Collapse
|
10
|
Sakthiswary R, Rajalingam S, Hussein H, Sridharan R, Asrul AW. Cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and its correlation with sonographic knee cartilage thickness and disease activity. Clin Rheumatol 2017; 36:2683-2688. [DOI: 10.1007/s10067-017-3817-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2016] [Revised: 08/09/2017] [Accepted: 09/01/2017] [Indexed: 01/04/2023]
|
11
|
Serum and synovial cartilage oligomeric matrix protein levels in early and established rheumatoid arthritis. Z Rheumatol 2017; 75:917-923. [PMID: 26683321 DOI: 10.1007/s00393-015-1647-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
OBJECTIVE To assess cartilage oligomeric matrix protein (COMP) levels in serum and synovial fluid in patients with early and established rheumatoid arthritis (RA), and to correlate the levels with clinical, laboratory and radiological characteristics. PATIENTS AND METHODS The study included 24 female RA patients. Full medical history was taken, thorough clinical examination and laboratory investigations performed, and body mass index (BMI) recorded. Radiological damage was assessed according to the modified Larsen score. Disease activity score 28 (DAS28) was calculated. The control group comprised 30 age- and gender-matched healthy subjects. Serum and synovial COMP levels were determined by enzyme-linked immunosorbent assay (ELISA). RESULTS Mean patient age was 44.04 ± 10.5 years. Of the 24 patients, 12 had early RA and 12 had established disease with joint destruction; 5 of each group had knee effusion. Serum COMP was significantly higher in patients (19.54 ± 5.47 µg/ml) compared to controls (5.93 ± 1.95 µg/ml; p < 0.001) and was also significantly higher in patients with established disease (23.9 ± 3.1 µg/ml) compared to those in early stages (15.1 ± 3.2 µg/ml; p < 0.001). Synovial COMP was also significantly increased in established compared to early-stage RA (31.2 ± 9.8 µg/ml vs. 51.6 ± 10.4 µg/ml; p = 0.013). Serum and synovial COMP significantly correlated with age, disease duration, BMI, DAS28 and modified Larsen score. On performing regression analysis in RA patients, only BMI could predict the serum level of COMP (p = 0.02). CONCLUSION COMP is a promising biomarker for disease activity in RA, making it a potential therapeutic target. The obvious correlation with the BMI throws light on the importance of weight control not only in osteoarthritis (OA), but also in RA.
Collapse
|
12
|
Boman A, Kokkonen H, Ärlestig L, Berglin E, Rantapää-Dahlqvist S. Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis. Clin Rheumatol 2017; 36:1005-1012. [PMID: 28190118 PMCID: PMC5400786 DOI: 10.1007/s10067-017-3570-4] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2016] [Revised: 01/22/2017] [Accepted: 01/31/2017] [Indexed: 01/25/2023]
Abstract
The aim of this study was to analyze relationships between receptor activator of nuclear factor kappa-B (RANKL), sclerostin and their gene polymorphisms with radiological progression in patients with early rheumatoid arthritis (RA). Patients with early RA (n = 407, symptomatic <1 year) (ARA criteria) examined radiologically at inclusion and after 24 months were consecutively included. Disease activity score and C-reactive protein were regularly recorded. Sclerostin, RANKL, and anti-CCP2 antibodies were analyzed in plasma at baseline using ELISAs. Data on gene polymorphism for sclerostin and RANKL were extracted from Immunochip analysis. Sex- and age-matched controls (n = 71) were identified from the Medical Biobank of Northern Sweden. The concentration of RANKL was significantly higher in patients compared with controls, median (IQR) 0.56 (0.9) nmol/L and 0.20 (0.25) nmol/L (p < 0.001), and in anti-CCP2-positive patients compared with sero-negative individuals. Sclerostin was significantly increased in female patients 0.59 (0.47–0.65) ng/mL compared with female controls 0.49 (0.4–0.65) ng/mL (p < 0.02). RANKL concentration was related to the Larsen score at baseline (p < 0.01), after 24 months (p < 0.001), and to radiological progression at 24 months (p < 0.001). Positivity of RANKL and anti-CCP2 yielded significant risk for progression with negativity for both as reference. No single nucleotide polymorphism encoding TNFSF11 or SOST was associated with increased concentrations of the factors. The concentration of RANKL was related to the Larsen score at baseline, at 24 months, and radiological progression at 24 months particularly in anti-CCP2-positive patients, while the concentration of sclerostin was unrelated to radiological findings.
Collapse
Affiliation(s)
- Antonia Boman
- Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, SE-901 85, Umeå, Sweden
| | - Heidi Kokkonen
- Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, SE-901 85, Umeå, Sweden
| | - Lisbeth Ärlestig
- Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, SE-901 85, Umeå, Sweden
| | - Ewa Berglin
- Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, SE-901 85, Umeå, Sweden
| | | |
Collapse
|
13
|
The Role of 25-Hydroxyvitamin D as a Predictor of Clinical and Radiological Outcomes in Early Onset Rheumatoid Arthritis. J Clin Rheumatol 2017; 23:33-39. [DOI: 10.1097/rhu.0000000000000477] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
14
|
Boyapati A, Msihid J, Fiore S, van Adelsberg J, Graham NMH, Hamilton JD. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY. Arthritis Res Ther 2016; 18:225. [PMID: 27716324 PMCID: PMC5052933 DOI: 10.1186/s13075-016-1132-9] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Accepted: 09/20/2016] [Indexed: 12/17/2022] Open
Abstract
Background Interleukin 6 (IL-6) signaling plays a key role in the pathophysiology of rheumatoid arthritis (RA) and is inhibited by sarilumab, a human monoclonal antibody blocking the IL-6 receptor alpha (IL-6Rα). The effects of sarilumab plus methotrexate (MTX) on serum biomarkers of joint damage and bone resorption were assessed in two independent studies (phase II (part A) and phase III (part B)) of patients with RA with a history of inadequate response to MTX from the MOBILITY study (NCT01061736). Methods Serum samples were analyzed at baseline and prespecified posttreatment time points. Biomarkers of tissue destruction, cartilage degradation, and synovial inflammation were measured in part A; assessment of these markers was repeated in part B and included additional analysis of biomarkers of bone formation and resorption (including soluble receptor activator of nuclear factor-kB ligand (sRANKL)). A mixed model for repeated measures was used to compare treatment effects on change in biomarkers. Additionally, changes from baseline in biomarkers were compared between American College of Rheumatology 50 % responders and nonresponders and between patients who achieved or did not achieve low disease activity (LDA), separately by treatment group, at week 24. Results In part A, sarilumab 150 and 200 mg every 2 weeks (q2w) significantly reduced biomarkers of tissue destruction, cartilage degradation, and synovial inflammation at both 2 and 12 weeks posttreatment (p < 0.05 vs placebo). These results were replicated in part B, with markers of these damaging processes reduced at weeks 2 and 24 (p < 0.05 vs placebo). Additionally, sarilumab 200 mg q2w significantly reduced both sRANKL and sRANKL/osteoprotegerin ratio at week 24 (p < 0.01 vs placebo). Trends for reduction were noted for several biomarkers in patients who achieved LDA compared with those who did not. Conclusions Sarilumab plus MTX significantly suppressed biomarkers of bone resorption and joint damage, as compared with placebo plus MTX, in patients with RA. Additional work is needed to determine whether differences in biomarker profiles at baseline or posttreatment can identify patients who achieve improvement in disease activity. Trial registration ClinicalTrials.gov, NCT01061736, February 2, 2010.
Collapse
Affiliation(s)
- Anita Boyapati
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA.
| | - Jérôme Msihid
- Sanofi R&D, 1 Avenue Pierre Brossolette, 91380, Chilly-Mazarin, France
| | - Stefano Fiore
- Sanofi US, 55 Corporate Drive, Bridgewater, NJ, 08807, USA
| | - Janet van Adelsberg
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA
| | - Neil M H Graham
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA
| | - Jennifer D Hamilton
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA
| |
Collapse
|
15
|
Quintana-Duque MA, Rondon-Herrera F, Mantilla RD, Calvo-Paramo E, Yunis JJ, Varela-Nariño A, Restrepo JF, Iglesias-Gamarra A. Predictors of remission, erosive disease and radiographic progression in a Colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study. Clin Rheumatol 2016; 35:1463-73. [PMID: 27041382 DOI: 10.1007/s10067-016-3246-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2015] [Revised: 02/14/2016] [Accepted: 03/22/2016] [Indexed: 12/22/2022]
Abstract
The objective of the study is to find predictors of remission, radiographic progression (RP), and erosive disease in a cohort of patients with early onset rheumatoid arthritis (EORA) that followed a therapeutic protocol aiming at remission, in a real world tight-control setting. EORA patients were enrolled in a 3-year follow-up study. Clinical, biological, immunogenetic, and radiographical data were analyzed. Radiographs were scored according to Sharp-van der Heijde (SvdH) method. RP was defined by an increase of 3 units in 36 months. Remission was defined as DAS28 <2.6. A stepwise multiple logistic regression model was used to identify independent predictors of the three target outcomes. One hundred twenty-nine patients were included. Baseline disease activity was high. Significant overall improvement was observed, but only 33.3 % achieved remission. At 36 month, 50.4 % (65) of patients showed erosions. RP was observed in 62.7 % (81) of cases. Statistical analysis showed that baseline SvdH score was the only predictive factor associated with the three outcomes evaluated. Lower HAQ-DI and absence of autoantibodies were predictive of remission. Higher levels of ESR and presence of erosions at entry were predictive of RP. Independent baseline predictors of incident erosive disease were anti-CCP and RF positivity, symptom duration at baseline >3 months, and presence of HLA-DRB1 shared epitope. Radiographic damage at baseline was the main predictor of outcomes. Autoantibodies, HAQ and ESR at baseline, symptom duration before diagnosis, and HLA-DRB1 status had influence on clinical course and development of structural joint damage in Colombian RA patients.
Collapse
Affiliation(s)
- M A Quintana-Duque
- Rheumatology Unit, Faculty of Medicine, National University of Colombia, Cra. 30 No. 45-03, Bldg 471, 5th Floor, Office 510, Bogota, Colombia.
| | - F Rondon-Herrera
- Rheumatology Unit, Faculty of Medicine, National University of Colombia, Cra. 30 No. 45-03, Bldg 471, 5th Floor, Office 510, Bogota, Colombia
| | - R D Mantilla
- Rheumatology Unit, Faculty of Medicine, National University of Colombia, Cra. 30 No. 45-03, Bldg 471, 5th Floor, Office 510, Bogota, Colombia
| | - E Calvo-Paramo
- Radiology Unit, Faculty of Medicine, National University of Colombia, Bogota, Colombia
| | - J J Yunis
- Pathology unit, Genetic Institute, Faculty of Medicine, National University of Colombia, Bogota, Colombia
| | - A Varela-Nariño
- Rheumatology Unit, Faculty of Medicine, National University of Colombia, Cra. 30 No. 45-03, Bldg 471, 5th Floor, Office 510, Bogota, Colombia
| | - J F Restrepo
- Rheumatology Unit, Faculty of Medicine, National University of Colombia, Cra. 30 No. 45-03, Bldg 471, 5th Floor, Office 510, Bogota, Colombia
| | - A Iglesias-Gamarra
- Rheumatology Unit, Faculty of Medicine, National University of Colombia, Cra. 30 No. 45-03, Bldg 471, 5th Floor, Office 510, Bogota, Colombia
| |
Collapse
|
16
|
Mohan C, Assassi S. Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity? BMJ 2015; 351:h5079. [PMID: 26612523 PMCID: PMC6882504 DOI: 10.1136/bmj.h5079] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Serological and proteomic biomarkers can help clinicians diagnose rheumatic diseases earlier and assess disease activity more accurately. These markers have been incorporated into the recently revised classification criteria of several diseases to enable early diagnosis and timely initiation of treatment. Furthermore, they also facilitate more accurate subclassification and more focused monitoring for the detection of certain disease manifestations, such as lung and renal involvement. These biomarkers can also make the assessment of disease activity and treatment response more reliable. Simultaneously, several new serological and proteomic biomarkers have become available in the routine clinical setting--for example, a protein biomarker panel for rheumatoid arthritis and a myositis antibody panel for dermatomyositis and polymyositis. This review will focus on commercially available antibody and proteomic biomarkers in rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (scleroderma), dermatomyositis and polymyositis, and axial spondyloarthritis (including ankylosing spondylitis). It will discuss how these markers can facilitate early diagnosis as well as more accurate subclassification and assessment of disease activity in the clinical setting. The ultimate goal of current and future biomarkers in rheumatic diseases is to enable early detection of these diseases and their clinical manifestations, and to provide effective monitoring and treatment regimens that are tailored to each patient's needs and prognosis.
Collapse
Affiliation(s)
- Chandra Mohan
- Department of Biomedical Engineering, University of Houston, Houston, TX 77204, USA
| | - Shervin Assassi
- Division of Rheumatology, University of Texas Health Science Center at Houston, Houston
| |
Collapse
|
17
|
Hensvold AH, Joshua V, Li W, Larkin M, Qureshi F, Israelsson L, Padyukov L, Lundberg K, Defranoux N, Saevarsdottir S, Catrina AI. Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate. Arthritis Res Ther 2015; 17:239. [PMID: 26337028 PMCID: PMC4559929 DOI: 10.1186/s13075-015-0760-9] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2015] [Accepted: 08/18/2015] [Indexed: 11/10/2022] Open
Abstract
INTRODUCTION Receptor activator of nuclear factor kappa B ligand (RANKL) is a key regulator of bone metabolism. Anti-citrullinated protein antibodies (ACPA) have been suggested to cause bone destruction by osteoclast activation. We investigated the relationship between RANKL and ACPA in patients with early untreated rheumatoid arthritis (RA). METHODS Patients with newly diagnosed untreated RA (n = 183) were analyzed at baseline and 3 months after initiating methotrexate (MTX) treatment. Serum RANKL (total RANKL), ACPA (anti-CCP2) and ACPA specificities (anti-citrullinated (cit)-vimentin, anti-cit-enolase and anti-cit-fibrinogen) were determined by enzyme-linked immunosorbent assay (ELISA). Synovial RANKL expression was evaluated by immunohistochemistry in a small group of patients (n = 15). The relationship between anti-cit-vim antibodies and bone destruction was further validated in 1116 RA patients included in the EIRA cohort. Pearson's chi-square test, Wilcoxon rank sum test, Wilcoxon signed rank test and linear regression models were used. RESULTS Serum RANKL concentration was significantly higher (p <0.05) in ACPA-positive (median: 689 pmol/L, IQR 342-1253) compared with ACPA-negative (median: 159 pmol/L, IQR 96-243) patients and this difference was also seen for synovial RANKL expression. Serum RANKL associated with ACPA (p <0.05) and bone erosions in rheumatoid factor (RF)-negative patients (n = 59). Among ACPA specificites, anti-cit-vimentin (amino acids 60-75) was associated with higher RANKL concentration and higher prevalence of bone erosion (p <0.05). Significant reductions in both serum RANKL and ACPA levels were observed after 3 months of MTX treatment (p <0.05). CONCLUSIONS RANKL was elevated in ACPA-positive and in anti-cit-vimentin-positive patients with early untreated RA and associated with bone erosions. These findings give further support for an early direct pathogenic link between ACPA and bone destruction in RA.
Collapse
Affiliation(s)
- Aase Haj Hensvold
- Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, L8:04 CMM, 171 76, Stockholm, Sweden.
| | - Vijay Joshua
- Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, L8:04 CMM, 171 76, Stockholm, Sweden.
| | - Wanying Li
- Crescendo Bioscience, 341 Oyster Point Boulevard, South San Francisco, CA, 94080, USA.
| | - Michaela Larkin
- Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, L8:04 CMM, 171 76, Stockholm, Sweden.
| | - Ferhan Qureshi
- Crescendo Bioscience, 341 Oyster Point Boulevard, South San Francisco, CA, 94080, USA.
| | - Lena Israelsson
- Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, L8:04 CMM, 171 76, Stockholm, Sweden.
| | - Leonid Padyukov
- Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, L8:04 CMM, 171 76, Stockholm, Sweden.
| | - Karin Lundberg
- Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, L8:04 CMM, 171 76, Stockholm, Sweden.
| | - Nadine Defranoux
- Crescendo Bioscience, 341 Oyster Point Boulevard, South San Francisco, CA, 94080, USA.
| | - Saedis Saevarsdottir
- Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, L8:04 CMM, 171 76, Stockholm, Sweden. .,Institute of Environmental Medicine, Karolinska Institutet, Solnavägen 1, 171 77, Stockholm, Sweden.
| | - Anca Irinel Catrina
- Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, L8:04 CMM, 171 76, Stockholm, Sweden.
| |
Collapse
|
18
|
Law RJ, Saynor ZL, Gabbitas J, Jones J, Kraus A, Breslin A, Maddison PJ, Thom JM. The Effects of Aerobic and Resistance Exercise on Markers of Large Joint Health in Stable Rheumatoid Arthritis Patients: A Pilot Study. Musculoskeletal Care 2015; 13:222-35. [PMID: 25962747 DOI: 10.1002/msc.1103] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
OBJECTIVE Exercise is beneficial for people with rheumatoid arthritis (RA). However, patients and health professionals have expressed concern about the possible detrimental effects of exercise on joint health. The present study investigated the acute and chronic effects of high-intensity, low-impact aerobic and resistance exercise on markers of large joint health in RA. METHODS Eight RA patients and eight healthy, matched control (CTL) participants performed 30 minutes' high-intensity, low-impact aerobic and lower-body resistance exercise, one week apart. Primary outcome measures assessing joint health were serum cartilage oligomeric matrix protein (sCOMP) and knee joint synovial inflammation (Doppler ultrasound colour fraction; CF). These measures were taken at baseline, immediately after and 0.5, one, two, six and 24 hours post-exercise. In a separate study, nine RA patients completed eight weeks of progressive exercise training. The same outcome measures were reassessed at baseline, and at one hour post-exercise of training weeks 0, 1, 4 and 8. RESULTS RA patients showed higher overall sCOMP [RA: 1,347 ± 421, CTL: 1,189 ± 562 ng/mL; p < 0.05; effect size (ES) = 0.32] and CF when scanned longitudinally (RA: 0.489 ± 0.30 × 10(-3) , CTL: 0.101 ± 0.13 × 10(-3) ; p < 0.01; ES = 1.73) and transversely (RA: 0.938 ± 0.69 × 10(-3) , CTL: 0.199 ± 0.36 × 10(-3) ; p < 0.01; ES = 1.33) than CTL. However, no acute effects on joint health were observed post-exercise. Similarly, no chronic effects were observed over eight weeks of combined aerobic and resistance training in RA, with positive effects on physical fitness and function. CONCLUSIONS RA patients on stable treatment with low disease activity were able to perform an individually prescribed high-intensity, low-impact aerobic and resistance exercise without changes in markers of large joint health. Copyright © 2015 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Rebecca-Jane Law
- North Wales Centre for Primary Care Research, Bangor University, Bangor, UK.,School of Sport, Health and Exercise Sciences, Bangor University, Bangor, UK
| | - Zoe L Saynor
- Department of Sport and Exercise Science, University of Portsmouth, Portsmouth, UK
| | - Julia Gabbitas
- School of Sport, Health and Exercise Sciences, Bangor University, Bangor, UK
| | - Jeremy Jones
- School of Sport, Health and Exercise Sciences, Bangor University, Bangor, UK.,Peter Maddison Rheumatology Centre, Betsi Cadwaladr University Health Board, Llandudno, UK
| | - Alexandra Kraus
- Radiology Department, Betsi Cadwaladr University Health Board, Bangor, UK
| | - Anne Breslin
- Peter Maddison Rheumatology Centre, Betsi Cadwaladr University Health Board, Llandudno, UK
| | - Peter J Maddison
- School of Sport, Health and Exercise Sciences, Bangor University, Bangor, UK
| | - Jeanette M Thom
- School of Sport, Health and Exercise Sciences, Bangor University, Bangor, UK.,School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
| |
Collapse
|
19
|
Investigating the Robustness and Diagnostic Potential of Extracellular Matrix Remodelling Biomarkers in Alkaptonuria. JIMD Rep 2015; 24:29-37. [PMID: 25786641 DOI: 10.1007/8904_2015_430] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/28/2014] [Revised: 02/09/2015] [Accepted: 02/23/2015] [Indexed: 03/07/2023] Open
Abstract
BACKGROUND AND AIM Alkaptonuria (AKU) clinical manifestations resemble severe arthritis. The Suitability of Nitisinone in Alkaptonuria 1 (SONIA 1) study is a dose-finding trial for nitisinone treatment of AKU patients. We tested a panel of serum and urinary biomarkers reflecting extracellular matrix remodelling (ECMR) of cartilage, bone and connective tissue in SONIA 1 patients to identify non-invasive and diagnostic biomarkers of tissue turnover in AKU. METHODS Fasted serum and urine were retrieved from 40 SONIA 1 patients and 44 healthy controls. Established biomarkers of bone remodelling (CTX-I, P1NP, OC), cartilage remodelling (CTX-II, C2M, AGNx1) and inflammation (CRPM) as well as exploratory biomarkers of ECMR (C6M, VCANM, MIM, TIM) were measured at baseline in serum and urine by means of enzyme-linked immunosorbent assays (ELISAs) or automated systems (Elecsys 2010). RESULTS The levels of bone resorption (CTX-I) and cartilage degradation (C2M) were elevated in AKU patients as compared to controls (p > 0.0001 and p = 0.03, respectively). Also tissue inflammation (CRPM) was elevated in AKU patients (p = 0.01). In addition all four exploratory biomarkers of ECMR (C6M, VCANM, MIM, TIM) were elevated in AKU patients compared to healthy controls. CTX-II was the only biomarker to be reduced in AKU patients. TIM was the only marker that showed a higher concentration than the normal assay range in AKU patients. CONCLUSIONS We have identified new potential biomarkers for assessment of cartilage, bone and cardiovascular remodelling in AKU and demonstrated the robustness of the assays used to measure the biomarker concentration in biological fluids.
Collapse
|
20
|
Engelmann R, Wang N, Kneitz C, Müller-Hilke B. Bone resorption correlates with the frequency of CD5⁺ B cells in the blood of patients with rheumatoid arthritis. Rheumatology (Oxford) 2014; 54:545-53. [PMID: 25193807 DOI: 10.1093/rheumatology/keu351] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
OBJECTIVE The prevention of bone resorption and subsequent joint destruction is one of the main challenges in the treatment of patients suffering from RA. Various mechanisms have previously been described that contribute to bone resorption in tightly defined cohorts. Here we analysed a cross-sectional cohort of RA patients and searched for humoral and cellular markers in the peripheral blood associated with bone resorption. METHODS We enrolled 61 consecutive RA patients positive for ACPA. Blood was analysed by flow cytometry to determine the percentages of regulatory T cells and B cell subpopulations. Cytokine (TNF-α, IL-6, IL-10) and ACPA levels as well as the bone resorption marker CTX-1 were determined from the patients' sera. Standard clinical disease parameters were included. RESULTS Multivariate analyses showed that the percentages of CD5(+) B cells were positively correlated with CTX-1 serum levels. However, neither low-avidity ACPA nor serum IL-6 levels, both known to be produced by CD5(+) cells, were associated with CTX-1 in patients' sera. There was no correlation between CTX-1 levels and clinical parameters or ACPA levels. CONCLUSION In summary, we found that the CD5(+) B cell population is associated with bone resorption as measured via serum CTX-1 levels in a cross-sectional cohort of RA patients. However, a possible functional link between CD5(+) B cells and bone resorption still needs to be defined.
Collapse
Affiliation(s)
- Robby Engelmann
- Institute of Immunology, Rostock University Medical Center, Rostock, Germany, Institute of Blood Research, Dalian Blood Center, Liaoning Province, China and Klinik für Innere Medizin II, Klinikum Südstadt Rostock, Rostock, Germany.
| | - Ni Wang
- Institute of Immunology, Rostock University Medical Center, Rostock, Germany, Institute of Blood Research, Dalian Blood Center, Liaoning Province, China and Klinik für Innere Medizin II, Klinikum Südstadt Rostock, Rostock, Germany. Institute of Immunology, Rostock University Medical Center, Rostock, Germany, Institute of Blood Research, Dalian Blood Center, Liaoning Province, China and Klinik für Innere Medizin II, Klinikum Südstadt Rostock, Rostock, Germany
| | - Christian Kneitz
- Institute of Immunology, Rostock University Medical Center, Rostock, Germany, Institute of Blood Research, Dalian Blood Center, Liaoning Province, China and Klinik für Innere Medizin II, Klinikum Südstadt Rostock, Rostock, Germany
| | - Brigitte Müller-Hilke
- Institute of Immunology, Rostock University Medical Center, Rostock, Germany, Institute of Blood Research, Dalian Blood Center, Liaoning Province, China and Klinik für Innere Medizin II, Klinikum Südstadt Rostock, Rostock, Germany
| |
Collapse
|
21
|
Navarro-Compán V, Landewé R, Provan SA, Ødegård S, Uhlig T, Kvien TK, Keszei AP, Ramiro S, van der Heijde D. Relationship between types of radiographic damage and disability in patients with rheumatoid arthritis in the EURIDISS cohort: a longitudinal study. Rheumatology (Oxford) 2014; 54:83-90. [PMID: 25065011 DOI: 10.1093/rheumatology/keu284] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVE The aim of this study was to assess if any of the different types of radiographic damage [true joint space narrowing (JSN), (sub)luxation and erosions] are preferentially related to disability in patients with RA. METHODS Longitudinal data from 167 RA patients from the European Research on Incapacitating Diseases and Social Support study over 10 years were analysed to investigate the relationship between the three types of radiographic damage and disability [grip strength, HAQ and the dexterity scale in the Arthritis Impact Measurement Scales (AIMS)]. A longitudinal analysis including separate models per type of damage and joint group and combined models including all information was conducted. RESULTS All types of damage were inversely related to grip strength in the analysis of separate models, but only true JSN independently remained statistically significant in the combined analysis [β = -0.087 (95% CI -0.151, -0.022)]. Neither JSN, (sub)luxation nor erosions were associated with HAQ score, while erosions were associated with AIMS dexterity only in the analysis of separate models. After stratifying for hand joint group, erosions at MCP joints [β = -0.288 (95% CI -0.556, -0.019)] and true JSN at the wrist [β = -0.132 (95% CI -0.234, -0.030)] were significantly related to grip strength. Erosions at the PIP [β = 0.017 (95% CI 0.005, 0.028)] and MCP joints [β = 0.114 (95% CI 0.010, 0.217)] was the only type of damage associated with HAQ and AIMS dexterity, respectively. CONCLUSION All types of radiographically visible joint damage interfere with important aspects of physical functions. True JSN is most closely related to hand function.
Collapse
Affiliation(s)
- Victoria Navarro-Compán
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, University Hospital La Paz, Madrid, Spain, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, Department of Rheumatology, Atrium Medical Center Heerlen, Heerlen, The Netherlands, Department of Rheumatology, Diakonhjemmet Hospital, National Unit on Rehabilitation in Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal. Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, University Hospital La Paz, Madrid, Spain, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, Department of Rheumatology, Atrium Medical Center Heerlen, Heerlen, The Netherlands, Department of Rheumatology, Diakonhjemmet Hospital, National Unit on Rehabilitation in Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal.
| | - Robert Landewé
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, University Hospital La Paz, Madrid, Spain, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, Department of Rheumatology, Atrium Medical Center Heerlen, Heerlen, The Netherlands, Department of Rheumatology, Diakonhjemmet Hospital, National Unit on Rehabilitation in Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal. Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, University Hospital La Paz, Madrid, Spain, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, Department of Rheumatology, Atrium Medical Center Heerlen, Heerlen, The Netherlands, Department of Rheumatology, Diakonhjemmet Hospital, National Unit on Rehabilitation in Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal
| | - Sella A Provan
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, University Hospital La Paz, Madrid, Spain, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, Department of Rheumatology, Atrium Medical Center Heerlen, Heerlen, The Netherlands, Department of Rheumatology, Diakonhjemmet Hospital, National Unit on Rehabilitation in Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal
| | - Sigrid Ødegård
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, University Hospital La Paz, Madrid, Spain, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, Department of Rheumatology, Atrium Medical Center Heerlen, Heerlen, The Netherlands, Department of Rheumatology, Diakonhjemmet Hospital, National Unit on Rehabilitation in Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal. Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, University Hospital La Paz, Madrid, Spain, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, Department of Rheumatology, Atrium Medical Center Heerlen, Heerlen, The Netherlands, Department of Rheumatology, Diakonhjemmet Hospital, National Unit on Rehabilitation in Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal
| | - Till Uhlig
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, University Hospital La Paz, Madrid, Spain, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, Department of Rheumatology, Atrium Medical Center Heerlen, Heerlen, The Netherlands, Department of Rheumatology, Diakonhjemmet Hospital, National Unit on Rehabilitation in Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal. Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, University Hospital La Paz, Madrid, Spain, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, Department of Rheumatology, Atrium Medical Center Heerlen, Heerlen, The Netherlands, Department of Rheumatology, Diakonhjemmet Hospital, National Unit on Rehabilitation in Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal
| | - Tore K Kvien
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, University Hospital La Paz, Madrid, Spain, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, Department of Rheumatology, Atrium Medical Center Heerlen, Heerlen, The Netherlands, Department of Rheumatology, Diakonhjemmet Hospital, National Unit on Rehabilitation in Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal
| | - András P Keszei
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, University Hospital La Paz, Madrid, Spain, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, Department of Rheumatology, Atrium Medical Center Heerlen, Heerlen, The Netherlands, Department of Rheumatology, Diakonhjemmet Hospital, National Unit on Rehabilitation in Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal
| | - Sofia Ramiro
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, University Hospital La Paz, Madrid, Spain, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, Department of Rheumatology, Atrium Medical Center Heerlen, Heerlen, The Netherlands, Department of Rheumatology, Diakonhjemmet Hospital, National Unit on Rehabilitation in Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal. Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, University Hospital La Paz, Madrid, Spain, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, Department of Rheumatology, Atrium Medical Center Heerlen, Heerlen, The Netherlands, Department of Rheumatology, Diakonhjemmet Hospital, National Unit on Rehabilitation in Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal
| | - Désirée van der Heijde
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, University Hospital La Paz, Madrid, Spain, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, Department of Rheumatology, Atrium Medical Center Heerlen, Heerlen, The Netherlands, Department of Rheumatology, Diakonhjemmet Hospital, National Unit on Rehabilitation in Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal. Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, University Hospital La Paz, Madrid, Spain, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, Department of Rheumatology, Atrium Medical Center Heerlen, Heerlen, The Netherlands, Department of Rheumatology, Diakonhjemmet Hospital, National Unit on Rehabilitation in Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands and Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal
| |
Collapse
|
22
|
Anti-granulocyte scintigraphy in early rheumatoid arthritis — does it work? Open Med (Wars) 2013. [DOI: 10.2478/s11536-013-0203-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Abstract
Collapse
|
23
|
Siebuhr AS, Bay-Jensen AC, Leeming DJ, Plat A, Byrjalsen I, Christiansen C, van de Heijde D, Karsdal MA. Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res Ther 2013; 15:R86. [PMID: 23945134 PMCID: PMC3978450 DOI: 10.1186/ar4266] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2012] [Accepted: 08/14/2013] [Indexed: 01/28/2023] Open
Abstract
Introduction Rheumatoid arthritis (RA) patients with structural progression are in most need of immediate treatment to maintain tissue integrity. The serum protein fingerprint, type I collagen degradation mediated by matrix metalloproteinases (MMP)-cleavage (C1M), is a biomarker of tissue destruction. We investigated whether baseline serum C1M levels could identify structural progressors and if the biomarker levels changed during anti-inflammatory treatment with tocilizumab (TCZ). Methods The LITHE-biomarker study (NCT00106535, n = 585) was a one-year phase III, double-blind, placebo (PBO)-controlled, parallel group study of TCZ 4 or 8 mg/kg every four weeks, in RA patients on stable doses of methotrexate (MTX). Spearman's ranked correlation was used to assess the correlation between baseline C1M levels and structural progression at baseline and at weeks 24 and 52. Multivariate regression was performed for delta structural progression. Change in C1M levels were studied as a function of time and treatment. Results At baseline, C1M was significantly correlated to C-reactive protein (P <0.0001), visual analog scale pain (P <0.0001), disease activity score28-erythrocyte sedimentation rate (DAS28-ESR) (P <0.0001), joint space narrowing (JSN) (P = 0.0056) and modified total Sharp score (mTSS) (P = 0.0006). Baseline C1M was significantly correlated with delta-JSN at Week 24 (R2 = 0.09, P = 0.0001) and at Week 52 (R2 = 0.27, P <0.0001), and with delta-mTSS at 24 weeks (R2 = 0.006, P = 0.0015) and strongly at 52 weeks (R2 = 0.013, P <0.0001) in the PBO group. C1M levels were dose-dependently reduced in the TCZ + MTX group. Conclusions Baseline C1M levels correlated with worsening joint structure over one year. Serum C1M levels may enable identification of those RA patients that are in most need of aggressive treatment Trial registration ClinicalTrials.gov: NCT00106535
Collapse
|
24
|
Andersson MLE, Svensson B, Petersson IF, Hafström I, Albertsson K, Forslind K, Heinegård D, Saxne T. Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis. BMC Musculoskelet Disord 2013; 14:229. [PMID: 23915292 PMCID: PMC3750296 DOI: 10.1186/1471-2474-14-229] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2013] [Accepted: 07/29/2013] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Currently available biomarkers for the early tissue process leading to joint damage in rheumatoid arthritis are insufficient and lack prognostic accuracy, possibly a result of variable activity of the disease over time. This study represents a novel approach to detect an altered activity of the disease process detected as increasing serum-COMP levels over a short time and whether this would correlate with joint damage progression over the first 5 years of disease. METHODS In all, 349 patients from the Swedish BARFOT early RA study were examined. Serum-COMP was analysed by ELISA at diagnosis and after 3 months. Based on changes in serum-COMP levels, three subgroups of patients were defined: those with unchanged levels (change ≤ 20%) (N=142), decreasing levels (> 20%) (N=173) and increasing levels (> 20%) (N=34). Radiographs of hands and feet were obtained at inclusion, after 1, 2 and 5 years and scored according to Sharp van der Heijde (SHS). Radiographic progression was defined as increase in SHS by ≥5.8. RESULTS The group of patients with increasing COMP levels showed higher median change in total SHS and erosion scores at 1, 2 and 5 year follow-up compared with the groups with stable or decreasing COMP levels. Furthermore, the odds ratio of radiographic progression was 2.8 (95% CI 1.26-6.38) for patients with increasing COMP levels vs. patients with unchanged levels.The group of patients with increasing COMP levels had higher ESR at inclusion but there were no baseline differences between the groups for age, gender, disease duration, disease activity (DAS28), function (HAQ), CRP, nor presence of rheumatoid factor or anti-CCP. Importantly, neither did changes over the 3-month period in DAS28, HAQ, ESR nor CRP differ between the groups and these variables did not correlate to joint damage progression. CONCLUSION Increasing serum-COMP levels between diagnosis and the subsequent 3 months in patients with early RA represents a novel indicator of an activated destructive process in the joint and is a promising tool to identify patients with significant joint damage progression during a 5-year period.
Collapse
|
25
|
Verstappen SM. Outcomes of early rheumatoid arthritis – The WHO ICF framework. Best Pract Res Clin Rheumatol 2013; 27:555-70. [DOI: 10.1016/j.berh.2013.09.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2013] [Revised: 09/20/2013] [Accepted: 09/24/2013] [Indexed: 12/19/2022]
|
26
|
Engvall IL, Svensson B, Boonen A, van der Heijde D, Lerner UH, Hafstrom I. Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP--a possible mechanism for specific inhibition of radiological destruction. Rheumatology (Oxford) 2012; 52:733-42. [DOI: 10.1093/rheumatology/kes369] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
|
27
|
Lee SH, Lin CY, Wang PH, Han CP, Yang SF, Chang JT, Lee MC, Lin LY, Lee MS. Significant association of elevated concentration of plasma YKL-40 with disease severity in patients with pelvic inflammatory disease. J Clin Lab Anal 2012; 26:136-42. [PMID: 22628227 DOI: 10.1002/jcla.21500] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
INTRODUCTION To date, no study reports the implication of YKL-40 in pelvic inflammatory disease (PID). Therefore, we investigate the levels of plasma YKL-40 in patients with PID and further associate its expression with the severity of disease. METHODS We designed a hospital-based case-control study with approximate 1:1 ratio and consecutively recruited 64 patients with PID and 70 control women. We collected blood samples from 64 women with PID before and after they received treatment and 70 control women to detect levels of plasma YKL-40 and C-reactive protein (CRP) as well as white blood cell and neutrophil counts. RESULTS The results revealed that levels of plasma YKL-40 were significantly elevated in patients with PID as compared to those in controls (38.36 vs. 21.69 ng/ml, P = 0.001) but the significant difference was restricted to women aged 30 years or old after age stratification (56.75 vs. 23.61 ng/ml, P ≤ 0.001). It declined significantly after they received treatment (median: 38.36 vs. 27.54 ng/ml; P ≤ 0.001). Although both plasma YKL-40 and CRP were elevated in patients with tubo-ovarian abscess, PID patients with surgery exhibited higher YKL-40 concentration than those without surgery (median: 82.05 vs. 30.19 ng/ml, P = 0.005) and only plasma YKL-40 was significantly associated with the length of the hospital stay (P ≤ 0.001, R = 0.604). CONCLUSION We conclude that once individuals are diagnosed to have PID, YKL-40 may act as a biomarker to predict the severity and clinical outcome of the disease.
Collapse
Affiliation(s)
- Shu-Hsin Lee
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Karsdal MA, Bay-Jensen AC, Henriksen K, Christiansen C. The pathogenesis of osteoarthritis involves bone, cartilage and synovial inflammation: may estrogen be a magic bullet? ACTA ACUST UNITED AC 2012; 18:139-46. [PMID: 23024184 DOI: 10.1258/mi.2012.012025] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The female predominance of polyarticular osteoarthritis (OA), and in particular the marked increase of OA in women after the menopause points to a likely involvement of female sex hormones in the maintenance of cartilage homeostasis. This perception has inspired many research groups to investigate the role of estrogens in the modulation of cartilage homeostasis with the ultimate aim to clarify whether estrogen replacement therapy (ERT) could provide benefits in preventing the rapid rise in the prevalence of OA in postmenopausal women. The effects of ERT and selective estrogen-receptor modulators on the joint in various experimental models have been investigated. Clinically, the effects of estrogens have been evaluated by post hoc analysis in clinical trials using biochemical markers of cartilage and bone degradation. Lastly, the Women's Health Initiative trial (WHI) investigated the effects of estrogens on the joint and joint replacements. Even though the exact mode of action still needs to be elucidated, the effect involves both direct and indirect mechanisms on the whole joint pathophysiology. Several animal models have demonstrated structural benefits of estrogens, as well as significant effects on joint inflammation. This is in complete alignment with clinical data using biochemical markers of joint degradation which demonstrated approximately 50% inhibition of cartilage destruction. These finding were recently validated in WHI, where women taking estrogens had significantly less joint replacement. In conclusion, the pleiotropic effect of estrogens on several different tissues may match the complicated aetiology of OA in some important aspects.
Collapse
Affiliation(s)
- M A Karsdal
- Nordic Bioscience A/S, Herlev Hovedgade 207, DK-2730 Herlev, Denmark.
| | | | | | | |
Collapse
|
29
|
Hjeltnes G, Hollan I, Førre Ø, Wiik A, Lyberg T, Mikkelsen K, Agewall S. Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF-α inhibitors. J Rheumatol 2012; 39:1341-7. [PMID: 22660798 DOI: 10.3899/jrheum.111401] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
OBJECTIVE To examine whether serum level of cartilage oligomeric matrix protein (S-COMP) is related to methotrexate (MTX) or to MTX and tumor necrosis factor-α (TNF-α) combination treatment for rheumatoid arthritis (RA); and to investigate whether S-COMP is related to cardiovascular risk factors including endothelial dysfunction and level of anticitrullinated protein antibodies (ACPA) in patients with RA. METHODS Clinical and laboratory measures, including S-COMP and reactive hyperemic index (RHI), were examined in 55 consecutive patients with RA starting with either MTX (n = 34) or MTX and anti-TNF-α treatment (n = 21) at baseline, and after 6 weeks and 6 months. RESULTS S-COMP was similar in the 2 treatment regimens during followup. We found a positive relationship between S-COMP at baseline and the use of disease-modifying antirheumatic drugs the last year preceding the study (p = 0.001), and a negative relation to current use of systemic glucocorticosteroids (p = 0.044). The nonsignificant change in S-COMP between baseline and the 6-month followup was positively and independently related to change in ACPA level (p = 0.009). There was no significant association between RHI and level of S-COMP at baseline. CONCLUSION The cartilage turnover marker S-COMP did not change significantly after 6 months' treatment with MTX with or without a TNF-α inhibitor in patients with RA. The positive association between S-COMP and ACPA suggests that these factors might interact, and could both be contributors to an unknown link between inflammation and cartilage destruction in patients with RA. S-COMP was not related to endothelial function in patients with RA, or to other cardiovascular risk factors studied. Clinical Trials registration number NCT00902005.
Collapse
Affiliation(s)
- Gunnbjørg Hjeltnes
- Lillehammer Hospital for Rheumatic Diseases, M. Grundtvigsv. 6, 2609 Lillehammer, Norway.
| | | | | | | | | | | | | |
Collapse
|
30
|
Serum osteoprotegerin concentration is associated with carotid atherosclerotic plaque in patients with rheumatoid arthritis. Mod Rheumatol 2012; 23:269-75. [PMID: 22584471 DOI: 10.1007/s10165-012-0654-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2012] [Accepted: 04/13/2012] [Indexed: 10/28/2022]
Abstract
OBJECTIVE Osteoprotegerin (OPG), a regulator of bone resorption, is involved in the pathogenesis of rheumatoid arthritis (RA) and atherosclerosis. OPG is elevated in patients with coronary artery disease, and high OPG levels are associated with cardiac disease severity and mortality in the general population. The purpose of this study was to investigate the relationship of serum OPG levels, traditional coronary risk factors, and RA-related factors to carotid atherosclerosis in RA patients. METHODS Ninety-one RA patients were studied (85 % women, age 60 ± 10 years). Serum OPG levels were measured by an enzyme-linked immunosorbent assay. The prevalence of carotid plaque was assessed by ultrasonographic imaging in all patients. The relationship between various clinical characteristics, OPG, and carotid plaque was examined. RESULTS Serum OPG levels were significantly higher in patients with carotid plaque than in those without plaque (median level 1,397 vs. 887 pg/mL, respectively; P = 0.006). There were no significant differences between RA patients with and without carotid plaque with respect to sex, duration of RA, blood pressure, body mass index, smoking, low-density lipoprotein cholesterol, Disease Activity Score-28, van der Heijde-modified Sharp score, and prednisolone dose. After adjusting for age, sex, and C-reactive protein, elevated levels of OPG were still associated with a higher prevalence of carotid plaque in patients with RA (P = 0.038). CONCLUSION RA patients suffer from accelerated atherosclerosis and also have increased levels of OPG. The serum OPG level is independently associated with carotid plaque.
Collapse
|
31
|
Karsdal MA, Schett G, Emery P, Harari O, Byrjalsen I, Kenwright A, Bay-Jensen AC, Platt A. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin Arthritis Rheum 2012; 42:131-9. [PMID: 22397953 DOI: 10.1016/j.semarthrit.2012.01.004] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2011] [Revised: 01/13/2012] [Accepted: 01/16/2012] [Indexed: 12/28/2022]
Abstract
OBJECTIVE To evaluate changes in biochemical markers of bone metabolism in response to tocilizumab in patients with anti-tumor necrosis factor-refractory rheumatoid arthritis (RA). METHODS RADIATE was a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial. C-reactive protein, osteocalcin (OC), C-terminal telopeptides of type-I collagen (C-terminal telopeptides of type-1 collagen (CTX-I) and type-I collagen degradation product), and matrix metalloproteinase-3 (MMP-3) serum levels were analyzed from 299 RA patients. Patients were randomly assigned to either tocilizumab (4 or 8 mg/kg) or placebo intravenously every 4 weeks, along with concomitant stable methotrexate (10 to 25 mg weekly) in all treatment arms. The change in biochemical markers CTX-I and OC in combination was evaluated as a measure of net bone balance, a reflection of the change in equilibrium between resorption and formation. RESULTS Both tocilizumab doses decreased C-reactive protein levels and significantly inhibited cathepsin K-mediated bone resorption in RADIATE subjects, as measured by a decrease in CTX-I. There was a significant overall improvement in net bone balance at week 16 as measured by a decrease in the CTX-I:OC ratio (-25%, P < 0.01). Furthermore, a significant reduction in MMP-3 (43%, P < 0.001) and type-I collagen degradation product levels (18%, P < 0.001) were observed following treatment, both consistent with decreased MMP-mediated type-I collagen catabolism in joint tissue. CONCLUSIONS In anti-tumor necrosis factor-refractory patients, tocilizumab significantly reduced the levels of biochemical markers of cathepsin K-mediated bone resorption and MMP-mediated tissue degradation and remodeling. These observations suggest that tocilizumab has a positive effect on bone balance, which could in part explain the retardation of progressive structural damage observed with tocilizumab. Clinical trial registry number: NCT00106522.
Collapse
|
32
|
Erlandsson MC, Forslind K, Andersson SEM, Lund A, Bokarewa MI. Metastasin S100A4 is increased in proportion to radiographic damage in patients with RA. Rheumatology (Oxford) 2012; 51:932-40. [DOI: 10.1093/rheumatology/ker362] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
|
33
|
Houseman M, Potter C, Marshall N, Lakey R, Cawston T, Griffiths I, Young-Min S, Isaacs JD. Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther 2012; 14:R30. [PMID: 22314025 PMCID: PMC3392825 DOI: 10.1186/ar3734] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2011] [Revised: 01/09/2012] [Accepted: 02/07/2012] [Indexed: 01/20/2023] Open
Abstract
Introduction At present, there is no reliable tool for predicting disease outcome in patients with rheumatoid arthritis (RA). We previously demonstrated an association between specific baseline biomarkers/clinical measures including matrix metalloproteinase-3 (MMP-3) and 2-year radiographic progression in patients with RA. This study further evaluates the predictive capability of these baseline variables with outcome extended over 8-years. Methods Fifty-eight of the original cohort (n = 118) had radiographic progression from baseline to mean 8.2-years determined using the van der Heijde modified Sharp method. The contribution of each predictor variable towards radiographic progression was assessed with univariate and multivariate analyses. Results Traditional factors (including erythrocyte sedimentation rate, C-reactive protein, anti-cyclic citrullinated peptide (anti-CCP), and rheumatoid factor) and biomarkers of tissue destruction (including MMP-3, C-telopeptide of type II collagen, cartilage oligomeric matrix protein, and tissue inhibitor of metalloproteinase 1) measured at baseline were associated with radiographic progression at endpoint. Multivariate logistic regression identified anti-CCP seropositivity [OR 9.29, 95%CI: 2.29-37.64], baseline elevated MMP-3 [OR 8.25, 95%CI: 2.54-26.78] and baseline radiographic damage [OR 5.83, 95%CI: 1.88-18.10] as the strongest independent predictors of radiographic progression. A model incorporating these variables had a predictive accuracy of 0.87, assessed using the area under the receiver operating characteristic curve. Conclusion In our cohort with onset of RA symptoms < 2-years, multivariate analysis identified anti-CCP status and baseline MMP-3 as the strongest independent predictors of radiographic disease outcome at 8.2-years. This finding suggests determination of baseline MMP-3, in conjunction with traditional serologic markers, may provide additional prognostic information for patients with RA. Furthermore, these findings highlight the importance of continued research into a broad range of biomarkers as potential predictors of joint damage.
Collapse
|
34
|
Molecular serum and urine marker repertoire supporting clinical research on joint diseases. Best Pract Res Clin Rheumatol 2011; 25:859-72. [DOI: 10.1016/j.berh.2011.11.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2011] [Accepted: 11/14/2011] [Indexed: 12/23/2022]
|
35
|
Abstract
Biomarkers have an important influence on the clinical decision-making processes involved in diagnosis, assessment of disease activity, allocation of treatment, and determining prognosis. The clinical usefulness of a biomarker is dependant on demonstration of its validity. Ideally, biomarkers should provide information not available from currently available tests and should be tested as they would be used in clinical practice; however, potential biomarkers could be affected by many different clinical or patient variables-such as disease activity, therapeutic intervention, or the presence of comorbidities--and validation studies might not include all the design features that are required to ensure that the biomarker is a true measure of the clinical process it is intended to reflect. In this Review, we appraise studies that have been conducted to validate six promising new biomarkers for diagnosis, disease activity assessment, or prognosis in patients with systemic autoimmune diseases. We discuss the validity of these six biomarkers with particular reference to the features of the studies that lend weight to or distract from their findings. The intent of this discussion is to draw attention to elements of validation study design that should be considered when evaluating the robustness of a biomarker, which differ according to the marker's intended use.
Collapse
|
36
|
Maehlen MT, Nordang GB, Syversen SW, van der Heijde DM, Kvien TK, Uhlig T, Lie BA. FCRL3 -169C/C genotype is associated with anti-citrullinated protein antibody-positive rheumatoid arthritis and with radiographic progression. J Rheumatol 2011; 38:2329-35. [PMID: 21885492 DOI: 10.3899/jrheum.110489] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
OBJECTIVE Studies of Caucasian populations have shown conflicting results concerning the association between a promoter polymorphism -169T>C of the Fc receptor-like 3 (FCRL3) gene and rheumatoid arthritis (RA). It is unknown whether FCRL3 is associated with autoantibody status and disease severity. We investigated associations between FCRL3 -169T>C and autoantibody status and joint damage in patients with RA. METHODS A total of 652 Norwegian patients with RA from 2 cohorts and 981 Norwegian controls, previously genotyped for FCRL3 -169T>C (rs7528684), were studied. Data on anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF) were available. The EURIDISS cohort (disease duration ≤ 4 yrs at baseline) was followed longitudinally, with assessment of radiographic hand damage at baseline and after 10 years (n = 117) according to the van der Heijde-modified Sharp score. RESULTS We found significant associations with ACPA-positive RA for both the C allele (OR 1.28, 95% CI 1.08-1.52, p = 0.004) and the C/C genotype (OR 1.57, 95% CI 1.18-2.10, p = 0.002). Similar associations were seen with RF-positive RA. No association was found with ACPA-negative or RF-negative RA. The C/C genotype was found to be associated with 10-year radiographic progression in multivariate linear and logistic regression analyses, after adjustment for ACPA, erythrocyte sedimentation rate, age, and sex. CONCLUSION The promoter polymorphism of FCRL3 was associated with autoantibody-positive RA. Despite the low number of patients, the C/C genotype of the FCRL3 polymorphism consistently and independently predicted radiographic progression. These findings suggest that FCRL3 is involved in both disease susceptibility and progression.
Collapse
Affiliation(s)
- Marthe T Maehlen
- Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
| | | | | | | | | | | | | |
Collapse
|
37
|
Bakker MF, Verstappen SMM, Welsing PMJ, Jacobs JWG, Jahangier ZN, van der Veen MJ, Bijlsma JWJ, Lafeber FPJG. The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial. Arthritis Res Ther 2011; 13:R70. [PMID: 21539729 PMCID: PMC3218879 DOI: 10.1186/ar3331] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2010] [Revised: 03/21/2011] [Accepted: 05/08/2011] [Indexed: 11/26/2022] Open
Abstract
Introduction The aim of this study was to investigate whether serum biomarker levels of C2C, C1,2C, CS846, and CPII can predict the long-term course of disease activity and radiographic progression early in the disease course of rheumatoid arthritis (RA). Methods In patients in the CAMERA trial, levels of biomarkers were evaluated at baseline and after 1 year of treatment. Relations of (changes in) biomarker values with the mean yearly radiographic progression rate and mean disease activity over a 5-year period were evaluated by using regression analysis. The added predictive value of biomarkers over established predictors for long-term outcome was analyzed by multiple linear regression analysis. Results Of 133 patients, serum samples were available at baseline and after 1 year of treatment. In the regression analysis C1,2C at baseline, the change in C2C, C1,2C, and the sum of the standardized changes in C2C + C1,2C scores were statistically significantly associated with the mean yearly radiographic progression rate; the change in CPII was associated with the mean disease activity over 5 years of treatment. In the multiple linear regression analysis, only the change in C1,2C was of added predictive value (P = 0.004) for radiographic progression. Explained variances of models for radiographic progression and disease activity were low (0.28 and 0.34, respectively), and the biomarkers only marginally improved the explained variance. Conclusions The change in C1,2C in the first year after onset of RA has a small added predictive value for disease severity over a 5-year period, but the predictive value of this biomarker combined with current predictive factors is too small to be of use for individual patients.
Collapse
Affiliation(s)
- Marije F Bakker
- Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Karsdal MA, Woodworth T, Henriksen K, Maksymowych WP, Genant H, Vergnaud P, Christiansen C, Schubert T, Qvist P, Schett G, Platt A, Bay-Jensen AC. Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities. Arthritis Res Ther 2011; 13:215. [PMID: 21539724 PMCID: PMC3132026 DOI: 10.1186/ar3280] [Citation(s) in RCA: 82] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease associated with potentially debilitating joint inflammation, as well as altered skeletal bone metabolism and co-morbid conditions. Early diagnosis and aggressive treatment to control disease activity offers the highest likelihood of preserving function and preventing disability. Joint inflammation is characterized by synovitis, osteitis, and/or peri-articular osteopenia, often accompanied by development of subchondral bone erosions, as well as progressive joint space narrowing. Biochemical markers of joint cartilage and bone degradation may enable timely detection and assessment of ongoing joint damage, and their use in facilitating treatment strategies is under investigation. Early detection of joint damage may be assisted by the characterization of biochemical markers that identify patients whose joint damage is progressing rapidly and who are thus most in need of aggressive treatment, and that, alone or in combination, identify those individuals who are likely to respond best to a potential treatment, both in terms of limiting joint damage and relieving symptoms. The aims of this review are to describe currently available biochemical markers of joint metabolism in relation to the pathobiology of joint damage and systemic bone loss in RA; to assess the limitations of, and need for additional, novel biochemical markers in RA and other rheumatic diseases, and the strategies used for assay development; and to examine the feasibility of advancement of personalized health care using biochemical markers to select therapeutic agents to which a patient is most likely to respond.
Collapse
Affiliation(s)
- Morten A Karsdal
- Nordic Bioscience, Herlev Hovedgade 207, DK-2730 Herlev, Denmark
- Southern University of Denmark (SDU), Campusvej 55DK-5230 Odense M Denmark
| | - Thasia Woodworth
- Leading Edge Clinical Research LLC, 3901 SE St Lucie Blvd unit 20, Stuart, Florida 34997, USA
| | - Kim Henriksen
- Nordic Bioscience, Herlev Hovedgade 207, DK-2730 Herlev, Denmark
| | - Walter P Maksymowych
- University of Alberta, 562 Heritage Medical Research Building, Edmonton, AB T6G 2S2, Canada
| | | | | | | | | | - Per Qvist
- Nordic Bioscience, Herlev Hovedgade 207, DK-2730 Herlev, Denmark
| | - Georg Schett
- University of Erlangen-Nurnberg Department of Internal Medicine, Krankenhausstraße 12, 91054 Erlangen, Germany
| | - Adam Platt
- Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, UK
| | | |
Collapse
|
39
|
Sanmartí R, Gómez-Puerta JA. [Biomarkers in rheumatoid arthritis]. ACTA ACUST UNITED AC 2011; 6S3:S25-8. [PMID: 21794768 DOI: 10.1016/j.reuma.2010.10.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2010] [Accepted: 10/30/2010] [Indexed: 01/12/2023]
Abstract
The search for biomarkers in rheumatoid arthritis (RA) has been the object of interesting research in the past few years, although results have not always been relevant. Several biomarkers, from several different locations (blood, urine, synovial fluid, synovial tissue) and of different nature (autoantibodies, genetic markers, joint remodeling markers), and related to different outcomes, diagnostic and prognostic markers (joint destruction, disability, lack of remission, mortality, response to anti-rheumatic treatment, etc.) have been studied. The present article reviews research only on soluble biomarkers, mainly those in serum, related to the diagnosis and joint destruction in RA.
Collapse
Affiliation(s)
- Raimon Sanmartí
- Unidad de Artritis, Servicio de Reumatología, Hospital Clínic de Barcelona, Barcelona, España.
| | | |
Collapse
|
40
|
Grandaunet B, Syversen SW, Hoff M, Sundan A, Haugeberg G, van Der Heijde D, Kvien TK, Standal T. Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis. ACTA ACUST UNITED AC 2011; 63:662-9. [DOI: 10.1002/art.30163] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
41
|
Wu T, Sajitharan D, Mohan C. Biomarkers of rheumatoid arthritis: recent progress. ACTA ACUST UNITED AC 2010; 4:293-305. [DOI: 10.1517/17530059.2010.492828] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
42
|
Bridges SL, Causey ZL, Burgos PI, Huynh BQN, Hughes LB, Danila MI, van Everdingen A, Ledbetter S, Conn DL, Tamhane A, Westfall AO, Jonas BL, Callahan LF, Smith EA, Brasington R, Moreland LW, Alarcón GS, van der Heijde DM. Radiographic severity of rheumatoid arthritis in African Americans: results from a multicenter observational study. Arthritis Care Res (Hoboken) 2010; 62:624-31. [PMID: 20461784 DOI: 10.1002/acr.20040] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE To describe radiographic changes in African Americans with rheumatoid arthritis (RA) from the Consortium for the Longitudinal Evaluations of African Americans with Early Rheumatoid Arthritis (CLEAR) Registry, a multicenter observational study. METHODS Self-declared African American patients were enrolled in CLEAR I, a longitudinal cohort of early RA (disease duration of <2 years) from 2000 to 2005, or in CLEAR II, a cross-sectional cohort (any disease duration) from 2006 to the present. Demographic and clinical data were obtained, and sets of hand/wrist and foot radiographs were scored using the modified Sharp/van der Heijde scoring system. RESULTS A total of 357 and 418 patients were enrolled in CLEAR I and CLEAR II, respectively. We report here an interim analysis of radiographic severity in these patients. For the CLEAR I cohort, 294 patients had a mean radiographic score of 2.89 at the baseline visit; 32.0% showed either erosions (25.9%) or joint space narrowing (JSN; 19.4%). At the 36-month visit, the mean score was 5.65; 44.2% had erosions, 41.5% had JSN, and 54.4% had either. Among those patients without radiographic damage at baseline, 18.9% had progressed at the 36-month visit, compared with 57.1% of those with baseline damage (P < 0.0001). For the CLEAR II cohort, of 167 patients with RA of any duration, 65.3% exhibited joint erosions, 65.3% exhibited JSN, and 74.8% exhibited either. The mean radiographic score was 33.42. CONCLUSION To our knowledge, this is the largest radiographic study of African American RA patients. Damage occurs early in the disease and is associated with radiographic progression at 3 years of disease duration. The CLEAR Registry will provide a valuable resource for future analyses of genetic, clinical, and environmental factors associated with radiographic severity of RA in African Americans.
Collapse
Affiliation(s)
- S Louis Bridges
- University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL 35294-2182, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Nam J, Villeneuve E, Emery P. The role of biomarkers in the management of patients with rheumatoid arthritis. Curr Rheumatol Rep 2009; 11:371-7. [PMID: 19772833 DOI: 10.1007/s11926-009-0053-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
In recent years, patient outcomes have improved dramatically with the availability of effective treatments for the management of rheumatoid arthritis (RA). RA, however, is a heterogeneous disease with variable disease progression and treatment response. Whereas some patients respond to a single disease-modifying antirheumatic drug, others require more intensive treatment strategies. Assessing disease severity at diagnosis and monitoring disease activity on an individual level would be a more accurate way of tailoring therapy, ensuring optimal treatment for those at greatest risk of disease progression, long-term disability, and joint damage without unnecessary overtreatment. Assessment of disease activity and severity is currently based on a combination of clinical and laboratory parameters that aid treatment decisions. Use of biomarkers may provide a more accurate means of objectively assessing the disease. This article reviews the role of biomarkers in the management of RA.
Collapse
Affiliation(s)
- Jackie Nam
- Academic Unit of Musculoskeletal Diseases, 2nd Floor Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, United Kingdom
| | | | | |
Collapse
|
44
|
Galectin-9 ameliorates immune complex-induced arthritis by regulating Fc gamma R expression on macrophages. Clin Immunol 2009; 133:382-92. [PMID: 19800850 DOI: 10.1016/j.clim.2009.09.004] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2009] [Revised: 09/07/2009] [Accepted: 09/08/2009] [Indexed: 11/22/2022]
Abstract
Galectin-9 up-regulated Fc gamma RIIb expression of mouse peritoneal macrophages in vitro but down-regulated Fc gamma RIII expression. Galectin-9-treated macrophages stimulated with immune complexes (IC) produced less TNFalpha and IL-1 beta but more IL-10 than PBS-treated macrophages. Macrophage enhancing effects on IC-induced C5a and neutrophil chemotactic activity were also diminished for galectin-9-treated macrophages. In galectin-9-treated mice, the severity of IC-induced arthritis was reduced, as were pro-inflammatory cytokine levels in inflamed joints and serum C5a. Fc gamma RIIb expression of macrophages from galectin-9-treated mice was up-regulated, whereas Fc gamma RIII expression was down-regulated. Macrophages from galectin-9-treated mice produced less TNFalpha and IL-1 beta but more IL-10 than PBS-treated mice. Disease severity of galectin-9-transgenic mice was milder than wild-type mice, whereas that of galectin-9-deficient mice was exaggerated. Furthermore, macrophage Fc gamma RIIb expression in galectin-9-deficient mice was down-regulated, while Fc gamma RIII expression was up-regulated. These results suggest that galectin-9 suppresses IC-induced inflammation partly by regulating Fc gamma R expression on macrophages.
Collapse
|
45
|
Mjaavatten MD, Haugen AJ, Helgetveit K, Nygaard H, Sidenvall G, Uhlig T, Kvien TK. Pattern of joint involvement and other disease characteristics in 634 patients with arthritis of less than 16 weeks' duration. J Rheumatol 2009; 36:1401-6. [PMID: 19487273 DOI: 10.3899/jrheum.081217] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE To investigate the distribution of joint involvement in a cohort of patients with very recent onset arthritis and describe the disease characteristics in these patients. METHODS A very early arthritis clinic (NOR-VEAC) was established as a multicenter study. General practitioners were asked to refer patients presenting with at least 1 swollen joint of maximum 16 weeks' duration. Clinical and laboratory markers were examined. RESULTS We included 634 patients during the first 3 years, with mean (25th-75th percentile) arthritis duration of 30 (11-63) days. Monoarthritis was present in 243 (38.3%) patients, 216 (34.1%) had oligoarthritis, and 175 (27.6%) polyarthritis. Patients with polyarthritis were older, had longer duration of arthritis, and were more frequently anti-cyclic citrullinated peptide antibody and rheumatoid factor-positive. Patients in all 3 joint pattern groups (mono-/oligo-/polyarthritis) reported substantial effect on physical function, pain, and fatigue and had elevated levels of acute-phase reactants. Knee or ankle arthritis was most frequent in patients with mono- and oligoarthritis, whereas small joint involvement was most frequent in patients with polyarthritis. CONCLUSION Patients with recent-onset arthritis report a substantial influence on health status. Mono- and oligoarthritis are at least as frequent as polyarthritis. Polyarthritic patients more frequently exhibit features associated with a worse outcome.
Collapse
|